Clinical trials: Chronic Constipation
Constipation, Chronic Idiopathic Constipation
BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults
The objective of this study is to evaluate a daily dose of BLI400 Laxative for safety and efficacy versus placebo in constipated adults.
- Conditions
- Constipation, Chronic Idiopathic Constipation, CIC
- Trial name
- NCT02819297
- Testing
- BLI400 Laxative
- Where
- 51 sites in United States
- Volunteers
- 1,020 people
- Sponsor
- Braintree Laboratories
Back Pain, Low Back Pain
Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.
This was a clinical effectiveness trial designed to compare the effectiveness, safety, and tolerability of treatment with tapentadol prolonged release with that of oxycodone/naloxone prolonged release in non-opioid pre-treated…
- Conditions
- Back Pain, Low Back Pain, Neuropathic Pain
- Trial name
- NCT01838616
- Testing
- Tapentadol Prolonged Release, Oxycodone/Naloxone Prolonged Release
- Where
- 50 sites in Austria, Germany and 2 more
- Volunteers
- 367 people
- Sponsor
- Grünenthal GmbH
Chronic Constipation
Laxative Effectiveness of a Phytotherapeutic Tea
The aim of this study is to evaluate the efficacy and safety of a phytotherapeutic laxative tea, composed by Pimpinella anisum, Foeniculum vulgare, Sambucus nigra and Cassia angustifolia, in a randomized crossover…
- Trial name
- NCT00872430
- Testing
- Klein Laxative Tea
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Constipation
Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain
The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of subcutaneous MOA-728 versus placebo in subjects with chronic non-malignant pain who have Opioid-Induced Constipation (OIC).
- Trial name
- NCT00529087
- Testing
- N-methylnaltrexone bromide (MOA-728)
- Where
- 78 sites in United States
- Volunteers
- 460 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Constipation
Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity
To evaluate the different effects of prucalopride and PEG 3350 + electrolytes on colon motor activity in subjects that are chronically constipated.
- Trial name
- NCT01707667
- Testing
- prucalopride, PEG 3350
- Where
- 3 sites in United States, Belgium and 1 more
- Volunteers
- 13 people
- Sponsor
- Shire
Constipation
Guideline to Implementation: A Rapid Clinical Care Pathway to Care for Patients Affected by Chronic Constipation
The study is being completed to test the pilot implementation of a rapid clinical care pathway for chronic constipation in the University of Michigan Gastroenterology clinic.
- Trial name
- NCT06352827
- Testing
- Survey
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Michigan
Male Subjects With Chronic Constipation
Evaluation of Prucalopride in Male Subjects With Chronic Constipation.
This is a multi-centre, randomised, parallel-group, double-blind, placebo-controlled phase III trial to evaluate the efficacy of prucalopride versus placebo over 12 weeks of treatment in male subjects with chronic constipation.
- Trial name
- NCT01147926
- Testing
- Prucalopride
- Where
- 73 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 374 people
- Sponsor
- Shire
Chronic Idiopathic Constipation
Efficacy and Safety of Vibrant Capsule vs. Vibrant Placebo for the Treatment of Chronic Idiopathic Constipation (CIC)
The was performed to assess the safety and efficacy of the vibrant capsule vs. placebo for the treatment of subjects with functional Constipation.
- Trial name
- CIC (NCT04458675)
- Testing
- Vibrant capsule
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Vibrant Ltd.
Chronic Idiopathic Constipation
Efficacy and Safety of Vibrant Capsule vs. Placebo for the Treatment of Chronic Idiopathic Constipation
The study is a prospective, randomized, multicenter, adaptive design, double blinded, placebo-controlled study, to evaluate the efficacy and safety of Vibrant Capsule vs.
- Trial name
- Vibrant (NCT03879239)
- Testing
- Vibrating capsule
- Where
- 8 sites in United States
- Volunteers
- 349 people
- Sponsor
- Vibrant Ltd.
Chronic Idiopathic Constipation
12-Week Study of Plecanatide for CIC (The National CIC3 Study)
The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.
- Trial name
- CIC (NCT02122471)
- Testing
- Plecanatide
- Where
- 167 sites in United States
- Volunteers
- 1,410 people
- Sponsor
- Bausch Health Americas, Inc.
Opioid Induced Bowel Dysfunction
Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain
The primary objective of the study is to evaluate the safety of single doses of oral naldemedine in adults physically dependent on opioids.
- Trial name
- NCT01122030
- Testing
- Naldemedine
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Shionogi
Endometriosis
Ulipristal for Endometriosis-related Pelvic Pain
The aim of this research is to assess the benefit of a medication (ulipristal) for alleviation of symptoms in women with chronic, endometriosis-related pelvic pain.
- Trial name
- NCT02213081
- Testing
- Ulipristal
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Northwestern University
Constipation
Study to Gather Information on the Acceptability of a New Flavor System With Increasing Levels of 2, 4, 6 g or Higher of Mannitol for PEG 3350 in Subjects Having Infrequent Bowel Movements.
Study to gather information on the acceptability of a new flavor system with increasing levels of 2, 4, 6 g or higher of the sugar alcohol Mannitol for Polyethylene glycol (PEG) 3350 a drug stimulating bowel movement to pass…
- Trial name
- NCT04534465
- Testing
- Polyethylene glycol (MiraLAX, BAY81-8430), Mannitol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Bayer
Chronic Idiopathic Constipation
Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation
Safety and Tolerability Extension Trial for Patients with Chronic Idiopathic Constipation (CIC)
- Trial name
- NCT01895543
- Testing
- Elobixibat 10 mg
- Where
- 62 sites in United States, Belgium and 8 more
- Volunteers
- 411 people
- Sponsor
- Ferring Pharmaceuticals
Chronic Constipation, Irritable Bowel Syndrome With Constipation
An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).
- Trial name
- NCT00765999
- Testing
- Linaclotide
- Where
- 118 sites in United States, Canada
- Volunteers
- 1,559 people
- Sponsor
- Forest Laboratories
Chronic Idiopathic Constipation
The Plecanatide Chronic Idiopathic Constipation (CIC) Study
This is a randomized, double-blind, placebo controlled, 12 week repeat oral dose, dose ranging study to determine the efficacy and safety of 3 doses of plecanatide compared to placebo in patients with Chronic Idiopathic…
- Trial name
- NCT01429987
- Testing
- plecanatide
- Where
- 121 sites in United States
- Volunteers
- 951 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome With Constipation, Chronic Constipation
An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).
- Trial name
- NCT00730171
- Testing
- Linaclotide
- Where
- 116 sites in United States
- Volunteers
- 1,743 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Opioid-Induced Constipation
A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain
MNTX 3201 is a Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of oral MNTX for the treatment of opioid induced constipation in…
- Trial name
- NCT01186770
- Testing
- Methylnaltrexone
- Where
- 2 sites in United States
- Volunteers
- 804 people
- Sponsor
- Bausch Health Americas, Inc.
Constipation
Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Subjects Aged ≥ 18 Years
The purpose of this trial is to evaluate the long-term (24 weeks) efficacy of prucalopride versus placebo in subjects aged 18 years and older with chronic constipation.
- Trial name
- SPD555-401 (NCT01424228)
- Testing
- prucalopride
- Where
- 60 sites in Belgium, Czechia and 7 more
- Volunteers
- 364 people
- Sponsor
- Shire
Chronic Idiopathic Constipation
Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo
The purpose of this study is to evaluate the bioequivalence of sprinkle and capsule formulations of lubiprostone, as compared to placebo, when administered orally in participants with Chronic Idiopathic Constipation (CIC).
- Trial name
- NCT03097861
- Testing
- Lubiprostone
- Where
- 67 sites in United States
- Volunteers
- 552 people
- Sponsor
- Sucampo Pharma Americas, LLC